Background: Paclitaxel is one of the most effective anticancer drugs ever developed. To prevent hazards associated with intravenous (IV) administration which include the formation of microbubbles, microbiological contamination and particulate matter, the suppliers recommend that an in-line IV filter should be used during the infusion of the chemotherapeutic agent. Methods: To rule out the possibility that polyethersulfone (PES) membranes retain the paclitaxel during filtration, we carried out specific tests. Paclitaxel retention by PES in-line IV filters was evaluated by a simulated-drug IV infusion and high-performance liquid chromatography analysis. Results: In our model of study, no variation of paclitaxel concentration was revealed before and after filtration using two different filter devices. Conclusions: The results suggest that, under our experimental conditions, paclitaxel concentration in saline solution remains constant before and after filtration. Indeed, our study indicates that the filters analyzed herein, other than preventing hazards associated with IV administration, do not retain paclitaxel, thus avoiding the reduction of the drug concentration and potency during filtration.

Keywords:
Drug recovery, Absorption, Insoluble drug, Filtration, Paclitaxel
1.
Liu SY, Song SX, Lin L, Liu X: Molecular mechanism of cell apoptosis by paclitaxel and pirarubicin in a human osteosarcoma cell line. Chemotherapy 2010;56:101–107.
2.
Christopeit M, Lenz G, Forstpointner R, Bartelheim K, Kühnbach R, Naujoks K, Schalhorn A: Nine months to progression using fourth-line liposomally encapsulated paclitaxel against hepatocellular carcinoma. Chemotherapy 2008;54:309–314.
3.
Zhao K, Ping W, Li Q, Hao S, Zhao L, Gao T, Zhou D: Aspergillus niger var. taxi, a new species variant of taxol-producing fungus isolated from Taxus cuspidata in China. J Appl Microbiol 2009;107:1202–1207.
4.
Trissel LA: Pharmaceutical properties of taxol and their effects on preparation and administration. Pharmacotherapy 1997;17:133S–139S.
5.
Solimando DA: Taxol package insert. Cancer Invest 1997;15:503.
6.
Szebeni J, Alving CR, Savay S, Barenholz Y, Priev A, Danino D, Talmon Y: Formation of complement-activating particles in aqueous solutions of Taxol possible role in hypersensitivity reactions. Int Immunopharmacol 2001;1:721–735.
7.
Bononi I, Balatti V, Gaeta S, Tognon M: Gram-negative bacterial lipopolysaccharide retention by a positively charged new-generation filter. Appl Environ Microbiol 2008;74:6470–6472.
8.
Baumgartner TG, Schmidt GL, Thakker KM, Sitren HS, Cerda JJ, Mahaffey SM, Copeland EM 3rd: Bacterial endotoxin retention by inline intravenous filters. Am J Hosp Pharm 1986;43:681–684.
9.
Horibe K, Mashima Y, Tashiro T, Yamamori H, Okui K: Evaluation of the endotoxin retention capabilities of inline intravenous filters. JPEN J Parenter Enteral Nutr 1990;14:56–59.
10.
Richards C, Grassby PF: A comparison of the endotoxin-retentive abilities of two ‘96-h’ in-line intravenous filters. J Clin Pharm Ther 1994;19:199–202.
11.
Vanhaecke E, De Muynck C, Remon JP, Colardyn F: Endotoxin removal by end-line filters. J Clin Microbiol 1989;27:2710–2712.
12.
Ortolano GA, Russell RL, Angelbeck JA, Schaffer J, Wenz B: Contamination control in nursing with filtration. 2. Emerging rationale for bedside (final) filtration of prestorage leukocyte-reduced blood products. J Infus Nurs 2004;27:157–165.
13.
Webster CS, Merry AF, Emmens DJ, Van Cotthem IC, Holland RI: A prospective clinical audit of central venous catheter use and complications in 1,000 consecutive patients. Anaesth Intensive Care 2003;31:80–86.
14.
Viale PH: Complications associated with implantable vascular access devices in the patient with cancer. J Infus Nurs 2003;26:97–102.
15.
Burke JP: Infection control – a problem for patient safety. N Engl J Med 2003;348:651–656.
16.
Lavery I: Infection control in IV therapy: a review of the chain of infection. Br J Nurs 2010;19:6.
17.
Kulawik D: Antimicrobial lock solutions: an approach to reduce catheter-related bacteremia. Nephrol Nurs J 2010;37:553–555, quiz 556.
18.
Rebmann T, Murphy CL: Preventing catheter-related bloodstream infections: an executive summary of the APIC elimination guide. Am J Infect Control 2010;38:846–848.
19.
Cicalini S, Calmieri F, Petrosillo N: Clinical review: new technologies for prevention of intravascular catheter-related infections. Crit Care 2004;8:157–162.
20.
Hadaway LC: Skin flora and infection. J Infus Nurs 2003;26:44–48.
21.
Foster J, Richards R, Showell M: Intravenous in-line filters for preventing morbidity and mortality in neonates. Cochrane Database Syst Rev 2006;2:CD005248.
22.
van den Hoogen A, Krediet TG, Uiterwaal CS, Bolenius JF, Gerards LJ, Fleer A: In-line filters in central venous catheters in a neonatal intensive care unit. J Perinat Med 2006;34:71–74.
23.
Newall F, Ranson K, Robertson J: Use of in-line filters in paediatric intravenous therapy. J Intraven Nurs 1998;21:166–170.
24.
van Lingen RA, Baerts W, Marquering AC, Ruijs GJ: The use of in-line intravenous filters in sick newborn infants. Acta Paediatr 2004;93:658–662.
25.
Lehr HA, Brunner J, Rangoonwala R, Kirkpatrick CJ: Particulate matter contamination of intravenous antibiotics aggravates loss of functional capillary density in postischemic striated muscle. Am J Respir Crit Care Med 2002;165:514–520.
26.
Stevens RF, Wilkins KM: Use of cytotoxic drugs with an end-line filter. A study of four drugs commonly administered to paediatric patients. J Clin Pharm Ther 1989;14:475–479.
27.
Taniguchi T, Yamamoto K, Kobayashi T: Precipitate formed by thiopentone and vecuronium cause pulmonary embolism. Can J Anaesth 1998;45:347–351.
28.
Wong J, Brugger A, Khare A, Chaubal M, Papadopoulos P, Rabinow B, Kipp J, Ning J: Suspensions for intravenous (I.V.) injection: a review of development, preclinical and clinical aspects. Adv Drug Deliv Rev 2008;60:939–954.
29.
Kipp J: The role of solid nanoparticle technology in the parenteral delivery of poor water-soluble drugs. Int J Pharm 2004;284:109–122.
30.
Gaucher G, Marchessault RH, Leroux JC: Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. J Control Release 2010;143:2–12.
31.
Ennis CE, Merritt RJ, Neff DN: In vitro study of in line filtration of medications commonly administered to paediatric cancer patients. JPEN J Parenter Enteral Nutr 1983;7:156–158.
32.
De Muynck C, De Vroe C, Remon JP, Colardyn F: Binding of drugs to end-line filters: a study of four commonly administered drugs in intensive care units. J Clin Pharm Ther 1988;13:335–340.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.